Mortality and prognostic factors in hospitalized COVID-19 patients with cancer: an analysis from a large healthcare system in the United States

Luis E Raez; Meri Tarockoff; Carlos Rodrigo Carracedo Uribe; Jianli Niu; Candice Sareli; Nithya Sundararaman; Jayme Ion; Paula Eckardt; Andres Alvarez-Pinzon; Atif Hussein

doi:10.21037/atm-22-1667

Mortality and prognostic factors in hospitalized COVID-19 patients with cancer: an analysis from a large healthcare system in the United States

Ann Transl Med. 2022 Oct;10(20):1090. doi: 10.21037/atm-22-1667.

Authors

Affiliations

¹ Department of Hematology-Oncology, Memorial Cancer Institute/Florida International University, Pembroke Pines, FL, USA.
² Department of Internal Medicine, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
³ Office of Human Research Memorial Health Care System, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
⁴ Division of Infectious Diseases, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.

Abstract

Background: To evaluate clinical outcomes in patients with malignancy who are SARS-CoV-2 (COVID-19) positive and investigate if factors such as age, gender, and race contribute to COVID-19 mortality in patients with malignancy.

Methods: Retrospective data was gathered from Memorial Healthcare System of COVID-19 patients hospitalized from March 1, 2020 to January 18, 2021. Active malignancy was defined as either receiving antineoplastic therapy or being under surveillance. The primary endpoint was in-hospital mortality. Descriptive statistics were used to summarize the characteristics and outcomes. Univariate and multivariate logistic analysis were performed to define baseline clinical characteristics potentially associated with mortality in cancer patients with COVID-19.

Results: A total of 4,870 COVID-19 patients were enrolled in the study, and 265 of those patients had a diagnosis of active malignancy. The study population was diverse which included non-Hispanic whites (NHW) 816 (16.8%), Hispanics 2,271 (46.6%) and Blacks 1,534 (31.5%). Of the cancer patients, 24.1% were NHW, 43% were Hispanic and 28.7% were Black. Amongst the races, 37.5% of in-hospital mortalities were NHW, while 18.4% were Hispanics and 19.7% were Black. The in-hospital mortalities amongst the two malignancy types, solid and hematological, accounted for 24.6% and 23.5% of deaths and they were not found to be statistically significant (P=0.845). After adjustments for age, gender and race were made, cancer was independently associated with an increased in-hospital mortality, with an adjusted odds ratio of 1.48 [95% confidence interval (CI): 1.08-2.01]. Increased age and elevated serum levels of creatinine and C-reactive protein (CRP) were associated with an increased risk of death in cancer patients with COVID-19.

Conclusions: COVID-19 in patients with cancer had poorer outcomes in comparison to those who were cancer-free. Both hematological and solid malignancies had similar in-hospital mortality rates. The highest in-hospital mortalities of cancer patients with COVID-19 were non-Hispanic whites in-comparison to Hispanics with the least. Age, elevated levels of creatinine and CRP were independently associated with increased risk of death in cancer patients hospitalized with COVID-19. The findings indicate the need for close surveillance and monitoring of these patients as they are more likely to have higher risk of death from COVID-19.

Keywords: Coronavirus-19 (COVID-19); SARS-CoV-2; anti-cancer treatment; immunotherapy.